Stephens Investment Management Group LLC Purchases 43,750 Shares of Insulet Corporation (NASDAQ:PODD)

Stephens Investment Management Group LLC grew its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 57.6% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 119,732 shares of the medical instruments supplier's stock after acquiring an additional 43,750 shares during the quarter. Stephens Investment Management Group LLC owned 0.17% of Insulet worth $31,443,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. Horizon Investments LLC raised its stake in shares of Insulet by 3.1% during the fourth quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier's stock worth $362,000 after acquiring an additional 42 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its stake in shares of Insulet by 2.3% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier's stock worth $552,000 after buying an additional 48 shares during the period. Sequoia Financial Advisors LLC increased its stake in shares of Insulet by 2.4% in the fourth quarter. Sequoia Financial Advisors LLC now owns 2,170 shares of the medical instruments supplier's stock worth $566,000 after buying an additional 50 shares during the period. Steward Partners Investment Advisory LLC increased its stake in shares of Insulet by 5.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,050 shares of the medical instruments supplier's stock worth $274,000 after buying an additional 50 shares during the period. Finally, Quadrant Capital Group LLC increased its stake in shares of Insulet by 4.9% in the fourth quarter. Quadrant Capital Group LLC now owns 1,092 shares of the medical instruments supplier's stock worth $285,000 after buying an additional 51 shares during the period.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of Insulet in a research note on Friday, May 30th. They issued a "buy" rating and a $380.00 target price on the stock. Truist Financial assumed coverage on shares of Insulet in a research note on Monday, June 16th. They issued a "buy" rating and a $365.00 target price on the stock. Wall Street Zen downgraded shares of Insulet from a "buy" rating to a "hold" rating in a research note on Saturday, June 14th. Wolfe Research raised shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 target price on the stock in a research note on Tuesday, May 13th. Finally, Citigroup reaffirmed a "buy" rating on shares of Insulet in a research note on Tuesday, July 8th. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $321.00.

Insider Transactions at Insulet

In related news, SVP John W. Kapples sold 5,278 shares of the company's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the transaction, the senior vice president owned 23,180 shares in the company, valued at $7,382,134.60. The trade was a 18.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.39% of the stock is currently owned by insiders.

Insulet Stock Down 0.6%

Shares of PODD stock traded down $1.72 during mid-day trading on Wednesday, reaching $288.27. 386,894 shares of the company's stock traded hands, compared to its average volume of 719,013. Insulet Corporation has a 12 month low of $173.00 and a 12 month high of $329.33. The company has a market cap of $20.29 billion, a P/E ratio of 51.85, a P/E/G ratio of 2.59 and a beta of 1.35. The company has a quick ratio of 3.63, a current ratio of 4.47 and a debt-to-equity ratio of 1.21. The company's 50-day moving average price is $309.06 and its 200-day moving average price is $280.56.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. Insulet had a net margin of 18.29% and a return on equity of 22.25%. The firm had revenue of $569.00 million for the quarter, compared to analysts' expectations of $543.20 million. During the same quarter in the previous year, the business posted $0.73 EPS. The company's quarterly revenue was up 28.8% on a year-over-year basis. On average, equities analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.